Navigation Links
Atrium shows a strong financial performance for its first quarter

Increase of 98% in net earnings from continuing operations during the first

quarter of 2008 to reach 10.5 million US dollars

All amounts in US dollars

QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX: ATB), a recognized leading developer, manufacturer and marketer of added value products for health and nutrition industries, announced today his financial results for the first quarter of 2008.

During the quarter ended March 31, 2008, Atrium recorded revenues from continuing operations of $65.8 million, which represents an increase of 83.2% compared to revenues of $35.9 million for the corresponding quarter in 2007. Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) from continuing operations for the first quarter of 2008 increased by 90.8% to $18.4 million when compared to US$9.6 million for the same period in 2007. For the quarter ended March 31, 2008, net earnings from continuing operations rose by 97.8% to US$10.5 million when compared to $5.3 million for the same period in 2007. The Company's total net earnings were US$14.7 million, an increase of 70.8% when compared to net earnings of $8.6 million for the corresponding period in 2007. Net earnings per share on a diluted basis for the first quarter of 2008 rose by 69.2% to $0.44 per share, compared to $0.26 per share for the same period in 2007.

"We are very satisfied with the strong financial results for the first quarter as the Mucos integration is going according to plan and as we experienced solid organic growth in the quarter. We have begun the integration of Multicare B.V., which was acquired on February 15. This acquisition respects perfectly our strategic acquisition program. Furthermore we remain confident that we will finalize the sale of the Active Ingredients and Specialty Chemicals Division ("AI&SC") in the upcoming weeks as announced on April 4, allowing us to focus on our Health and Nutrition Division, and generating value for our shareholders" said Mr. Pierre Fitzgibbon, Atrium's President and Chief Executive Officer.

"The sale of the division at an attractive price will give us the means to execute our strategy to become the leader in the high end nutritional supplements"said Mr. Pierre Laurin, Chairman of Atrium.

Cash flows from continuing operations (before changes in non-cash working capital items) for the first quarter of 2008 were $11.7 million, an increase of 87.3% compared to $6.2 million for the same period of the preceding year. As at March 31, 2008, the Company had a total debt amounting to $325 million while the Company had a revolving credit facility that provides $350 million of borrowing capacity with the possibility to increase it up to $425 million. In addition, the Company has additional capacity, through an unsecured loan, of $35.6 million which can be used in whole or in part from now until May 21, 2008.

Discontinued Operations - Active Ingredients and Specialty Chemicals (AI

& SC) Division

For the quarter ended March 31, 2008, the Active Ingredients & Specialty Chemicals Division, presented as discontinued operations, generated revenues of $68.0 million, which is an increase of 15.6% compared to revenues of $58.8 million recorded for the same period in 2007. For the first quarter of 2008, the EBITDA was $6.5 million compared to an EBITDA of $5.3 million for the corresponding period in 2007, an increase of 21.2 %.

About Atrium

Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of added value products for health and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 600 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at

Conference Call and Webcast

Atrium will hold its quarterly conference call and webcast to discuss its first quarter 2008 on Tuesday May 6, 2008 at 2:00 p.m. Eastern time. Participants may access the call by using the following numbers: 416-644-3416, 514-807-8791 or 1-800-731-5319. A live webcast is also available via the Company's website at in the "Investors" section. A replay of the webcast will also be available on our website for a period of 30 days. A copy of Atrium's interim unaudited financial statements will also be available on the Company's website.

Caution Regarding Non-GAAP Measures

This press release is based on reported earnings in accordance with Canadian generally accepted accounting principles (GAAP). It is also based on earnings before interest, income taxes, depreciation and amortization (EBITDA) and gross margin. These measures do not have a standardized meaning prescribed by GAAP; therefore, other issuers using these terms may calculate them differently. Management believes that a significant portion of the users of its Consolidated Financial Statements and MD&A analyze the Company's results based on these performance measures.

Cautionary Note and Forward-Looking Statements

This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.

Attachment: Financial summary

Atrium Innovations Inc.

Summary of Interim Consolidated Financial Statements

(in millions of US dollars except per share amounts)

Consolidated Results for the quarters ended March 31


2008 2007 Change

Revenues 65.8 35.9 83.2%

Gross Margin (1) 35.6 17.1 107.5%

54.1% 47.8%

EBITDA (2) 18.4 9.6 90.8%

28.0% 26.8%

Net Earnings from continuing operations 10.5 5.3 97.8%

Net Earnings form discontinued operations 4.2 3.3 27.3%

--- ---

Net earnings 14.7 8.6 70.8%

---- ---

Net earnings per share

Basic 0.46 0.28

Diluted 0.44 0.26

Cash flow from continuing operating

activities before changes in non-cash

operating working capital items 11.7 6.2 87.3%

Consolidated Balance Sheet

(unaudited) As at As at

March 31, Dec. 31,

2008 2007

Cash and Cash Equivalents 34.7 27.4

Other current assets 187.4 162.2

Goodwill 198.5 168.8

Intangible assets and deferred charges 195.9 177.9

Other long term assets 94.3 88.9

---- ----

Total assets 710.8 625.2

----- -----

Short-term liabilities 84.1 79.7

Long-term debt 325.4 279.0

Other long-term liabilities 62.9 55.6

Shareholders' equity 238.4 210.9

----- -----

Total liabilities and shareholder's equity 710.8 625.2

----- -----

(1) Gross margin means sales less cost of goods sold.

(2) EBITDA means earnings before interest, income taxes, depreciation and

amortization. Continuing operations, H&N division, supports now 100%

of the Head Office fees which is comparable to 2007.

SOURCE Atrium Innovations Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Atrium Innovations to Hold 2008 First Quarter Financial Results Conference Call and Webcast on May 6
2. Atrium Innovations to Hold 2007 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast on February 29
3. Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007
4. Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
5. Atrium Innovations Announces Management Changes
6. A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
9. UW paper in Science shows how some solids mimic liquids on nanoscale
10. New research shows that iPods do not interfere with cardiac pacemakers
11. New kind of transistor radios shows capability of nanotube technology
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  Clintrax Global, Inc., a ... North Carolina , today announced that the company has set ... represented a 391% quarter on quarter growth posted for Q3 of ... and Mexico , with the establishment ... in December 2015. --> United Kingdom ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):